Literature DB >> 8852396

Gene therapy of cancer.

A Bank1.   

Abstract

There are several approaches to the gene therapy of cancer. Genes can be introduced into cancer cells to either sensitize them for killing by subsequent treatment with drugs, or to normalize their growth. In addition, genes can be added to tumor cells to provoke an accentuated immune response against these cells leading to cancer cell death. Alternatively, drug resistance genes can be added to bone marrow cells which make these cells more resistant to the toxic effects of chemotherapy, and thus allow higher doses of these drugs to be given without myelotoxicity and with potentially greater tumor kill. Although gene therapy of cancer is at an early stage of development, some of these strategies are being used in approved clinical trials in cancer patients.

Entities:  

Mesh:

Year:  1995        PMID: 8852396     DOI: 10.1007/bf01571191

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  22 in total

Review 1.  Multidrug resistance.

Authors:  I Pastan; M M Gottesman
Journal:  Annu Rev Med       Date:  1991       Impact factor: 13.739

Review 2.  Genetically engineered tumor vaccines.

Authors:  D M Pardoll
Journal:  Ann N Y Acad Sci       Date:  1993-08-12       Impact factor: 5.691

Review 3.  Progress toward human gene therapy.

Authors:  A D Miller
Journal:  Blood       Date:  1990-07-15       Impact factor: 22.113

4.  Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1.

Authors:  B P Sorrentino; S J Brandt; D Bodine; M Gottesman; I Pastan; A Cline; A W Nienhuis
Journal:  Science       Date:  1992-07-03       Impact factor: 47.728

5.  Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs.

Authors:  C E Grant; G Valdimarsson; D R Hipfner; K C Almquist; S P Cole; R G Deeley
Journal:  Cancer Res       Date:  1994-01-15       Impact factor: 12.701

6.  Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-gamma in irradiated human melanoma cells.

Authors:  B Gansbacher; K Zier; K Cronin; P A Hantzopoulos; B Bouchard; A Houghton; E Gilboa; D Golde
Journal:  Blood       Date:  1992-12-01       Impact factor: 22.113

7.  Preselection of transduced murine hematopoietic stem cell populations leads to increased long-term stability and expression of the human multiple drug resistance gene.

Authors:  C Richardson; A Bank
Journal:  Blood       Date:  1995-10-01       Impact factor: 22.113

8.  Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells.

Authors:  S P Cole; K E Sparks; K Fraser; D W Loe; C E Grant; G M Wilson; R G Deeley
Journal:  Cancer Res       Date:  1994-11-15       Impact factor: 12.701

9.  Transfer and expression of the human multiple drug resistance gene in human CD34+ cells.

Authors:  M Ward; C Richardson; P Pioli; L Smith; S Podda; S Goff; C Hesdorffer; A Bank
Journal:  Blood       Date:  1994-09-01       Impact factor: 22.113

10.  Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer.

Authors:  R E Donahue; S W Kessler; D Bodine; K McDonagh; C Dunbar; S Goodman; B Agricola; E Byrne; M Raffeld; R Moen
Journal:  J Exp Med       Date:  1992-10-01       Impact factor: 14.307

View more
  1 in total

1.  In vivo assessment of simultaneous G1 cyclins silencing by a tumor-specific bidirectional promoter on the mammary tumor in nude mice.

Authors:  Gholamreza Mesbah; Fatemeh Namazi; Fatemeh T Shamsabadi; Zahra Maleki; Mehrab Nasirikenari; Majid Shahbazi
Journal:  Front Vet Sci       Date:  2022-08-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.